Limitless Possibilities
Through Exquisite Control

At IFM Therapeutics, we work to improve the lives of patients with inflammation-driven diseases and cancer by developing transformative medicines that precisely target the innate immune system.
Discover Our Mission arrow-button

Regulating
Immune Response

Our first-in-class medicines precisely control or enhance immune responses across disease indications.

Explore Our Approach arrow-button

A Leading Portfolio of
First-in-Class Small Molecules

We are working with a sense of urgency to develop novel drugs that meet the needs of patients with inflammation-driven diseases and cancer.

View Our Pipeline arrow-button

An Unprecedented Track Record

Since the inception of IFM, we have advanced multiple, novel programs from discovery to first-in-human studies and beyond.

IFM Therapeutics Has an Unprecedented Track Record

Among the team's achievements in the company's first 3.5 years has been the progression of 3 novel programs from the standing start through to the clinic and the closing of 2 major deals.

2015

Arrow-right
October

IFM Therapeutics founded to discover agonists of NLRP3 for cancer.

2016

Arrow-right
FEBRUARY

Novel and proprietary NLRP3 agonist leads identified

MAY

Novel and proprietary STING agonists discovered

JUNE

IFM Therapeutics's $27M Series A closed

2017

Arrow-right
SEPTEMBER

Preclinical PoC for both NLRP3 and STING agonists demonstrated

SEPTEMBER

$2.32B sale of IFM Uno to BMS closed; IFM Therapeutics, LLC created as a spin-out, and IFM Tre launched

2018

Arrow-right
FEBRUARY

BMS dosed initial patient with first-in-class NLRP3 agonist, IFM-1222

JULY

IFM Tre's $31M Series A financing closed (focus on NLRP3 antagonist)

2019

Arrow-right
FEBRUARY

IFM Due launched (focus on cGAS/STING antagonists)

MARCH

IFM Tre dosed initial subject with first-in-class NLRP3 antagonist, IFM-2427

APRIL

BMS dosed first patient with STING agonist, IFM-1364

MAY

$1.575B sale of IFM Tre to Novartis closed

NOVEMBER

IFM Quattro and IFM Discovery launched with $55.5M financing from Omega Funds, Atlas Venture and Abingworth